Rybelsus Tablets for Weight Loss: UK Approval, Results and Alternatives

Rybelsus tablets contain semaglutide, the same active ingredient as Wegovy and Ozempic, but they are not approved for weight loss in the UK. The MHRA licensed Rybelsus solely to treat type 2 diabetes. So while it does cause some weight reduction, the results are considerably more modest than the injectable alternatives, and you cannot get it on the NHS specifically to lose weight.

Why Rybelsus produces less weight loss than the injections#

Absorption is the core problem. Oral semaglutide has very low bioavailability. To absorb any meaningful amount, you must take the tablet on a completely empty stomach with no more than 120ml of plain water (roughly half a cup), then wait at least 30 minutes before eating, drinking anything other than water, or taking other medicines.

Skipping or shortening that 30-minute fast doesn't just reduce the dose slightly. It can cut absorption dramatically. Food, coffee, and even larger volumes of water interfere with the absorption enhancer (SNAC) that makes oral semaglutide possible at all. In practice, many people find this protocol difficult to stick to every single morning without exception.

The result is that even at the highest licensed dose of 14mg daily, blood levels of semaglutide are far lower than those achieved with once-weekly subcutaneous injections. The PIONEER clinical trial programme, which tested oral semaglutide across thousands of people with type 2 diabetes, found weight loss of roughly 3 to 5% of starting body weight over 26 weeks. For a person weighing 100kg, that is approximately 3 to 5kg over six months. Compare that with the STEP trials, which showed injectable semaglutide at 2.4mg weekly (Wegovy) producing around 15% weight loss in people with obesity.

How Rybelsus compares to licensed weight loss treatments#

Two licensed oral options for weight loss now exist in the UK alongside injectable treatments: Wegovy Tablets, which contains oral semaglutide and is indicated for obesity management with trial data showing around 17% weight loss, and Foundayo, which contains orforglipron — a different active ingredient — and produces around 11% weight loss in trials. Both matter enormously for anyone who has needle phobia or simply wants a pill-based option.

Can you get Rybelsus privately for weight loss?#

Yes, but it is off-label prescribing. Private clinicians can legally prescribe Rybelsus for weight loss if they judge it clinically appropriate for an individual patient. The GMC's Good Practice in Prescribing guidance requires that the prescriber explains the off-label status clearly, discusses the evidence, and documents their reasoning.

Before agreeing to off-label Rybelsus from a private prescriber, it is reasonable to ask:

• Is this use off-label, and have they documented why it is appropriate for you specifically?
• What monitoring will be in place (blood glucose, HbA1c, weight, blood pressure)?
• How often will you be reviewed?
• Are there MHRA-licensed alternatives with stronger evidence for weight loss?
• Does the pharmacy dispensing it hold a GPhC registration?

That last point matters. Private prescriptions for Rybelsus must still be dispensed by a registered UK pharmacy. Online services are legal to use as long as the pharmacy holds a current GPhC registration.

Who Rybelsus might still suit#

Despite its limitations for pure weight loss, Rybelsus can be a reasonable choice for a specific group: people who have already been diagnosed with type 2 diabetes, want blood sugar control and some weight reduction, and cannot tolerate injections for medical or psychological reasons. In this scenario, Rybelsus is on-label, the prescribing criteria are clear, and NHS prescribing is possible if diabetes-specific criteria are met.

Rybelsus is not suitable for everyone. You should not take it if you have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, a history of pancreatitis, severe gastrointestinal disease, or if you are pregnant or breastfeeding. It interacts with other medicines that require a consistent absorption window, particularly levothyroxine, which must be separated by at least 30 minutes. If you take any regular morning medicines, discuss timing carefully with your prescriber.

Side effects with oral versus injectable semaglutide#

The side effect profile is broadly the same: nausea, vomiting, diarrhoea, constipation, and reduced appetite. Because oral semaglutide delivers lower systemic exposure, some people experience milder gastrointestinal effects, though this is not guaranteed. Pancreatitis is a rare but serious risk with all GLP-1 medications. If you develop severe, persistent abdominal pain, stop the medicine and seek medical advice promptly.

You can report side effects from any medicine, including off-label use, to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Weight regain after stopping#

This applies to all GLP-1 medicines, not just Rybelsus. The appetite-suppressing effect is maintained only while you continue taking the medicine. Studies show that most weight returns within one to two years of stopping. This is not a personal failing; it reflects how GLP-1 receptors regulate appetite. Anyone considering Rybelsus or any semaglutide-based treatment should factor this into their decision.

A practical note for needle-averse readers#

If injections are the barrier, it is worth knowing that licensed oral options with better weight loss evidence than Rybelsus now exist. Totiva's weight loss service includes MHRA-licensed treatments including oral options, and a clinician will assess which is appropriate for your health profile. The consultation is free and you only pay if treatment is recommended and approved.

For most people without type 2 diabetes who want meaningful weight loss from a tablet, a licensed oral treatment will give you a stronger evidence base and clearer regulatory standing than off-label Rybelsus.